Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Purdue Pharma L.P.

News headline image
Bankruptcy Court to Confirm Purdue Pharma’s Plan of Reorganization
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Grants Orphan Drug Designation for Tinostamustine in Malignant Glioma
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Plan of Reorganization Receives Overwhelming Creditor Support
From Purdue Pharma L.P.
Via Business Wire
News headline image
New Study Examines Nalmefene Auto-Injector and Intranasal Naloxone for Reversal of Respiratory Depression Induced by Fentanyl in a Controlled Clinical Study
From Purdue Pharma L.P.
Via Business Wire
News headline image
Investigational Drug Tinostamustine to be Included in GBM AGILE Clinical Trial for Glioblastoma
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Expands its Provision of Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Receives Court Approval of Disclosure Statement Filed in Connection with its Plan of Reorganization
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Files New Plan of Reorganization Providing for More Than $7.4 Billion in Creditor Distributions
From Purdue Pharma L.P.
Via Business Wire
News headline image
New Study Explores Nalmefene and Naloxone for Reversal of Respiratory Depression Induced by Fentanyl in a Clinical Opioid Induced Respiratory Depression Model
From Purdue Pharma L.P.
Via Business Wire
News headline image
Study Examining Use of Nalmefene HCI Injection for Opioid Overdose Reversal in Emergency Departments Concludes Observational Period
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Approves Zurnai™ (nalmefene injection) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose Induced by Natural or Synthetic Opioids in Adults and Pediatric Patients 12 Years and Older
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Enters Agreement to Provide Low-Cost Opioid Use Disorder Treatment to Correctional Facilities for Incarcerated Individuals
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
From Purdue Pharma L.P.
Via Business Wire
News headline image
Harm Reduction Therapeutics Introduces RiVive™, Over-the-Counter Opioid Overdose Reversal Medication
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Approves Harm Reduction Therapeutics’ Over-the-Counter Opioid Overdose Reversal Medication
From Purdue Pharma L.P.
Via Business Wire
News headline image
Second Circuit Court Upholds Purdue Pharma’s Plan of Reorganization on Appeal
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
From Purdue Pharma L.P.
Via Business Wire
News headline image
Harm Reduction Therapeutics to Receive Additional Funding for its Low-Cost Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Grants Priority Review for Nalmefene Prefilled Syringe for the Treatment of Known or Suspected Opioid Overdose
From Purdue Pharma L.P.
Via Business Wire
News headline image
Prescription Drug Safety Network Reached More Than 22,000 Students with Prescription Drug Safety Digital Education During 2021-22 School Year
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma Introduces Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) in the U.S. for the Treatment of Known or Suspected Overdose with Natural or Synthetic Opioids
From Purdue Pharma L.P.
Via Business Wire
News headline image
Harm Reduction Therapeutics to Receive Additional Funding for the Development of its Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma after Bankruptcy Court Approval
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. to Provide Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal in Emergency Medicine Settings
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Approves Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) for the Treatment of Known or Suspected Opioid Overdose with Natural or Synthetic Opioids
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma Statement with Respect to District Court Decision Vacating Bankruptcy Court’s Confirmation of the Plan of Reorganization
From Purdue Pharma L.P.
Via Business Wire
News headline image
Confirmed Plan of Reorganization of Purdue Pharma L.P. Facilitates Creation of New Company – “Knoa Pharma”
From Purdue Pharma L.P.
Via Business Wire
News headline image
Plan of Reorganization of Purdue Pharma L.P. Receives Bankruptcy Court Approval
From Purdue Pharma L.P.
Via Business Wire
News headline image
Purdue Pharma L.P. Announces Preliminary Voting Results on Plan of Reorganization
From Purdue Pharma L.P.
Via Business Wire
News headline image
FDA Accepts Filing of Abbreviated New Drug Application and Grants Priority Review for Nalmefene HCI Injection for the Treatment of Known or Suspected Opioid Overdose
From Purdue Pharma L.P.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.